Classical genetics

Metropolitan Wins Top Honors for Best Tasting Tap Water in the U.S.

Retrieved on: 
Tuesday, June 8, 2021

Metropolitan garnered top honors in the municipal water category, with its member agency, the City of Santa Ana, coming in at second place.

Key Points: 
  • Metropolitan garnered top honors in the municipal water category, with its member agency, the City of Santa Ana, coming in at second place.
  • While water quality and safety are always our utmost priorities, its also important to us that consumers like the taste of our water.
  • Good taste is an important confirmation for consumers of the quality of the water coming from their taps, Metropolitan General Manager Jeffrey Kightlinger said.
  • Our panel of tasters take months-long training to become certified sensory analysts to ensure that our customers are receiving the best tasting drinking water.

Segra Enters Agreement to Offer Allele’s Proven Winner Cannabis Cultivar Collection Across Canada and International Markets

Retrieved on: 
Wednesday, March 10, 2021

VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) -- Segra International Corp. and Allele Genetics, a subsidiary of Catalyst BC, are pleased to announce they have entered into an exclusive agreement to distribute Alleles collection of data-backed Proven Winner cannabis cultivars within the Canadian market and other legal international markets.

Key Points: 
  • VANCOUVER, British Columbia, March 10, 2021 (GLOBE NEWSWIRE) -- Segra International Corp. and Allele Genetics, a subsidiary of Catalyst BC, are pleased to announce they have entered into an exclusive agreement to distribute Alleles collection of data-backed Proven Winner cannabis cultivars within the Canadian market and other legal international markets.
  • Amplifying Alleles Proven Winners with the power of Segras tissue culture technologies will ensure consistently high-performing plants that are, as with all Segra tissue culture plants, Verified Clean Stock.
  • Segra is thrilled to be partnering more closely with Allele and able to offer a portion of their data-backed collection, through tissue culture, to operators, said Segra CEO Jamie Blundell.
  • To learn more about this partnership and how Segra and Alleles Tissue Culture plantlets can improve your output and reduce risk, please contact Segra at [email protected] .

Stoke Therapeutics Announces Publication of Data in the Journal Nature Communications That Support the Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression

Retrieved on: 
Thursday, July 9, 2020

Rather than address genetic diseases by replacing, repairing or editing faulty genes, we set out to increase or stoke protein output from healthy genes.

Key Points: 
  • Rather than address genetic diseases by replacing, repairing or editing faulty genes, we set out to increase or stoke protein output from healthy genes.
  • These data show that we can increase full-length, fully functional protein expression from a variety of healthy genes, which supports our hypothesis and may lead to a new way of treating severe genetic diseases.
  • Stoke designed TANGO ASOs to target the non-productive splicing events in these genes and their activity was evaluated.
  • These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies.

New research casts doubt on near reality of 'designer babies'

Retrieved on: 
Thursday, November 21, 2019

However, there has been no research published to indicate the potential success of polygenic embryo selection.

Key Points: 
  • However, there has been no research published to indicate the potential success of polygenic embryo selection.
  • "Through our research, we can confidently say that trait predictions for embryos based on polygenic scores are not very accurate."
  • The research team hopes that this work will promote an open and evidence-based discussion of these aspects among the public and policymakers.
  • The Feinstein Institutes for Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York.

PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH

Retrieved on: 
Tuesday, September 24, 2019

The Platform has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.

Key Points: 
  • The Platform has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.
  • FibroNest is distributed worldwide on the cloud-based image Visualization and Analysis platform of ViQi, Inc of Santa Barbara, a strategic partner of PharmaNest.
  • Clients and investigators upload their images and receive phenotypic maps and an automated composite phenotypic fibrosis score for a project fee.
  • FibroNest has been engineered to quantify the fibrosis phenotype in three phenotypic dimensions including more than 40 traits and +350 parameters.